PUBLICAÇÕES científicas

/cun/pt/investigacion/publicaciones-cientificas/areaMain/02
  • Increase of the Adiponectin/Leptin Ratio in Patients with Obesity and Type 2 Diabetes after Roux-en-Y Gastric Bypass

    Unamuno X (1,2), Izaguirre M (1), Gómez-Ambrosi J (1,2,3), Rodríguez A (1,2,3), Ramírez B (1,2,3), Becerril S (1,2,3), Valentí V (2,3,4), Moncada R (2,3,5), Silva C (2,6), Salvador J (2,6), Portincasa P (7), Frühbeck G (1,2,3,6), Catalán V (8,9,10).

    (1) Metabolic Research Laboratory, Clínica Universidad de Navarra, 31008 Pamplona, Spain.
    (2) CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, 31008 Pamplona, Spain.
    (3) Obesity and Adipobiology Group, Instituto de Investigación Sanitaria de Navarra (IdiSNA), 31008 Pamplona, Spain.
    (4) Department of Surgery, Clínica Universidad de Navarra, 31008 Pamplona, Spain.
    (5) Department of Anesthesia, Clínica Universidad de Navarra, 31008 Pamplona, Spain.
    (6) Department of Endocrinology & Nutrition, Clínica Universidad de Navarra, 31008 Pamplona, Spain.
    (7) Clinica Medica "A. Murri", Department of Biomedical Sciences and Human Oncology, University of Bari "Aldo Moro" Medical School, 70124 Bari, Italy.
    (8) Metabolic Research Laboratory, Clínica Universidad de Navarra, 31008 Pamplona, Spain.
    (9) CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, 31008 Pamplona, Spain.
    (10) Obesity and Adipobiology Group, Instituto de Investigación Sanitaria de Navarra (IdiSNA), 31008 Pamplona, Spain. 

    Nutrients 03 de SETEMBRO de 2019

  • A phase I/II dose-escalation study investigating all-oral ixazomib-melphalan-prednisone induction followed by single-agent ixazomib maintenance in transplant-ineligible newly diagnosed multiple myeloma

    San-Miguel JF (1), Echeveste Gutierrez MA (2), Špicka I (3), Mateos MV (4), Song K (5), Craig MD (6), Bladé J (7), Hájek R (8), Chen C (9), Di Bacco A (10), Estevam J (10), Gupta N (10), Byrne C (10), Lu V (10), van de Velde H (10), Lonial S (11).

    (1) Clinica Universidad de Navarra, Centro Investigación Medica Aplicada (CIMA), El Instituto de Investigación Sanitaria de Navarra (IDISNA), Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Pamplona, Spain
    (2) Hospital Universitario Donostia, San Sebastián, Spain.
    (3) 1Medical Department - Clinical Department of Haematology, First Faculty of Medicine and General Teaching Hospital, Charles University, Prague, Czech Republic.
    (4) Hospital Universitario de Salamanca, Instituto Biosanitario de Salamanca (IBSAL), Spain.
    5 Division of Hematology, University of British Columbia, Vancouver, BC, Canada.
    (6) Department of Medicine, West Virginia University, Morgantown, WV, USA.
    (7) Department of Hematology, Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Spain.
    (8) Department of Haematooncology, University Hospital Ostrava, Faculty of Medicine, Ostrava University, Czech Republic.
    (9) Cancer Clinical Research Unit, Princess Margaret Cancer Center, Toronto, ON, Canada.
    (10) Millennium Pharmaceuticals, Inc., Cambridge, MA, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Atlanta, GA, USA.
    (11) Winship Cancer Institute of Emory University, Atlanta, GA, USA.

    Haematologica 01 de SETEMBRO de 2019

  • Identification of 58 Mutations (26 Novel) in 94 of 109 Symptomatic Spanish Probands with Protein C Deficiency

    Martos L (#1), Fernández-Pardo Á (#1), López-Fernández MF (2), Ibáñez F (3), Herrero S (4), Tàssies D 5, González-Porras JR (6), Solmoirago MJ (1), Costa MJ (2), Reverter JC (5), Marco P (7), Roldán V (8), Lecumberri R (9), Velasco F (10), Oto J (1), Iruin G (11), Alonso MN (12), Vayá A (1), Bonanad S (1,13), Ferrando F (1,13), Martí E (14), Cid AR (1,13), Plana E (1), Oña F (15), Cuesta I (16), González-López TJ (17), España F (1), Medina P (1), Navarro S (1); Working Group of the Spanish Society of Thrombosis Haemostasis (SETH).

    (1) Grupo de Investigación en Hemostasia, Trombosis, Arteriosclerosis y Biología Vascular, Instituto de Investigación Sanitaria La Fe (IIS La Fe), Hospital Universitario y Politécnico La Fe, Valencia, Spain.
    (2) Complejo Hospitalario Universitario A Coruña, A Coruña, Spain.
    (3) Hospital General Universitario de Valencia, Valencia, Spain.
    (4) Hospital Universitario de Guadalajara, Guadalajara, Spain.
    (5) Hospital Clinic de Barcelona, Barcelona, Spain.
    (6) Hospital Universitario de Salamanca-IBSAL, Salamanca, Spain.
    (7) Hospital General Universitario de Alicante, Alicante, Spain.
    (8) Hospital General Universitario Morales Meseguer, Murcia, Spain.
    (9) Clínica Universidad de Navarra, Pamplona, Spain.
    (10) Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), Córdoba, Spain.
    (11) Hospital de Cruces, Baracaldo, Bilbao, Spain.
    (12) Hospital Universitario Infanta Cristina, Badajoz, Spain.
    (13) Unidad de Trombosis y Hemostasia, Servicio de Hematología, Hospital Universitario y Politécnico La Fe, Valencia, Spain.
    (14) Hospital de Manises, Valencia, Spain.
    (15) Hospital Universitario de Getafe, Getafe, Madrid, Spain.
    (16) Hospital Obispo Polanco, Teruel, Spain.
    (17) Hospital Universitario de Burgos y Departamento de Ciencias de la Salud, Universidad de Burgos, Burgos, Spain.
    # Contributed equally

    Thrombosis and Haemostasia 01 de SETEMBRO de 2019

  • Feasibility of transaortic approach to map an atrial re-entrant tachycardia within the pulmonary venous atrium in a patient with d-transposition of the great arteries after Mustard operation by using a high-density mini-basket catheter

    Solimene F (1), Maddaluno F (2), Schillaci V (1), García-Bolao I (3).

    (1)Department of Electrophysiology, Clinica Montevergine, Mercogliano, Italy.
    (2) Boston Scientific, Italy.
    (3) Department of Cardiology and Cardiac Surgery, Clínica Universidad de Navarra, Pamplona, Spain.

    Journal of Cardiovascular Electrophysiology 26 de AGOSTO de 2019

  • Topical Ectoine: A Promising Molecule in the Upper Airways Inflammation-A Systematic Review

    Casale M (1), Moffa A (2), Carbone S (1), Fraccaroli F (1), Costantino A (1), Sabatino L (1), Lopez MA (1), Baptista P (3), Cassano M (2), Rinaldi V (1).

    (1) Unit of Otolaryngology, UOS ORL TI, Campus Bio-Medico University, Rome, Italy.
    (2) Unit of Otolaryngology, University of Foggia, Foggia, Italy.
    (3) Unit of Otolaryngology, Clinica Universitaria de Navarra, Pamplona, Spain.

    Biomed Research International 26 de AGOSTO de 2019

talvezlhe interesse

QUE TECNOLOGIA UTILIZAMOS? 

A Clínica é o hospital privado com maiores recursos tecnológicos de Espanha, tudo num único centro.

Imagen de un PET, tecnología de vanguardia en la Clínica Universidad de Navarra

OS NOSSOS
PROFISSIONAIS

Os profissionais da Clínica realizam um trabalho contínuo de investigação e formação, sempre em benefício do paciente.

Imagen profesionales de la Clínica Universidad de Navarra

RAZÕES PARA VIR
À CLÍNICA

Conheça porque é que somos diferentes em relação a outros centros sanitários. Qualidade, rapidez, comodidade e resultados.

Imagen del edificio de la Clínica Universidad de Navarra